CLDX
Celldex Therapeutics, Inc. Health Care In Vitro & In Vivo Diagnostic Substances Russell 3000
$30.10Close
$2.0BMarket cap
$22.58 – $44.8752-week range
Nov 9, 2026Next report
Highlights
Cautions
- Not in an uptrend 3 of 8 trend conditions
- Lagging the market RS 40 · weaker than 60% of stocks over 12 months
- Far from its high 33% below its 52-week high
- Distribution down-day volume 1.8× up-day volume over 50 sessions
- Results soon Nov 9, 2026, in 8 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
33%
1wk
up 2.9%
price change
1mo
down 7.1%
price change
12-month return
up 16%
market up 11% ·
its own up 5%
F-score
3 / 9
Weak
Altman Z
16.55
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
3.8×
price / book
Earnings yield
down 14.6%
EBIT / enterprise value
Cheaper than
19%
of the market · expensive
Revenue growth
down 78%
year on year
EPS growth
—
latest quarter
Sales growth
down 97%
latest quarter · +1 pts
ROE
down 41%
return on equity
Free cash margin
down 13829%
-$213.7M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- short-term liquidity weakened
- issued more shares
- gross margin narrowed
- assets working less efficiently
- profitability improving
- profits backed by cash
- reduced long-term debt
Trade setup
ATR%
4.6%
$1.39 a day · 2×ATR $27.32
RS
40 / 99
vs the universe
Trend
3 / 8
trend template
Relative volume
0.6×
vs 50-day average
Up/down volume
0.54
50 sessions
Implied move
—
no option chain · report Nov 9, 2026
Trend template · 3 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: fails
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Gross margin narrowing Gross margin fell from 97.2% to 87.1%. The company is keeping less of each dollar of sales than it did a year ago.
- Revenue shrinking Revenue fell 78.0% over the year, from $7.0M to $1.5M.
Last reported
Aug 6, 2026
Last shock
Sep 22, 2026-12% in one session11.5× volumeon an SEC filing-10% since
Financials
- Gross 87%
- Net -16748%
- Free cash -13829%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $7.4M | $4.7M | $2.4M | $6.9M | $7.0M | $1.5M |
| Gross margin | 97% | 98% | 96% | 96% | 97% | 87% |
| Operating income | -$63.4M | -$71.2M | -$115.2M | -$154.5M | -$195.1M | -$287.4M |
| Net income | — | -$70.5M | -$112.3M | -$141.4M | -$157.9M | -$258.8M |
| Net margin | — | -1516% | -4766% | -2055% | -2249% | -16748% |
| Earnings per share | — | -$1,644.76 | -$2,395.60 | -$2.92 | -$2.45 | -$3.90 |
| Free cash flow | -$42.0M | -$62.2M | -$105.6M | -$109.1M | -$159.7M | -$213.7M |
| Free cash margin | -566% | -1336% | -4479% | -1585% | -2275% | -13829% |
| Cash | $43.8M | $39.1M | $29.4M | $34.8M | $28.4M | $28.9M |
| Shareholders' equity | $209.4M | $419.5M | $326.2M | $429.2M | $747.0M | $527.2M |
| Shares outstanding | 39.60m | 46.73m | 47.20m | 55.88m | 66.37m | 66.55m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Feb 25, 2026 | Annual ↗ | Dec 31, 2025 | 56d |
| Nov 10, 2025 | Quarterly ↗ | Sep 30, 2025 | 41d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Nov 6, 2024 | Quarterly ↗ | Sep 30, 2024 | 37d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 6, 2024 | Quarterly ↗ | Mar 31, 2024 | 36d |
| Feb 26, 2024 | Annual ↗ | Dec 31, 2023 | 57d |
| Nov 2, 2023 | Quarterly ↗ | Sep 30, 2023 | 33d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 22, 2026 | Other events ↗ |
| Aug 6, 2026 | Results ↗ |
| Jul 15, 2026 | Director or officer change ↗ |
| Jun 26, 2026 | Director or officer change · Shareholder vote ↗ |
| May 7, 2026 | Results ↗ |
| Apr 2, 2026 | Material agreement · Other events ↗ |
| Feb 25, 2026 | Results ↗ |
| Nov 10, 2025 | Results ↗ |
| Aug 19, 2025 | Other events ↗ |
| Aug 7, 2025 | Results ↗ |
| Jun 6, 2025 | Director or officer change · Shareholder vote ↗ |
| May 8, 2025 | Results ↗ |